RecruitingNot ApplicableNCT06772935
Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer
Sponsor
Affiliated Hospital of Qinghai University
Enrollment
162 participants
Start Date
Jun 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Electroacupuncture treatment of peripheral neuropathy after taxane chemotherapy for breast cancer
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years
Inclusion Criteria7
- Breast cancer patients diagnosed by pathology;
- EOOG score is 0 or 1;
- The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination);
- ⑤ Previously received taxane chemotherapy for more than 6 months;
- ⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks;
- ⑦ Voluntarily participate in this clinical trial and sign the informed consent form;
- Accept regular follow-up visits; ⑨ There is complete pathological data available.
Exclusion Criteria10
- Non breast cancer patients;
- Received electroacupuncture treatment within 6 months prior to the start of the study;
- Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle;
- Prior to enrollment, there was a history of peripheral neuropathy;
- Unstable heart disease or myocardial infarction within the first 6 months of the study;
- ⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment;
- ⑦ Uncontrolled epilepsy patients with uncontrolled seizures;
- ⑧ Merge with other malignant tumor patients;
- ⑨ Pregnancy and lactation period;
- ⑩ Refusal to join clinical trial patients
Interventions
BEHAVIORALElectro-acupuncture
A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06772935
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location